X0306 4 2020-12-22 0 0001445283 YUMANITY THERAPEUTICS, INC. YMTX 0001697628 Peters Richard C/O YUMANITY THERAPEUTICS, INC 40 GUEST STREET, SUITE 4410 BOSTON MA 02135 1 1 0 0 President and CEO Stock Option (Right to Buy) 8.16 2020-12-22 4 A 0 235237 A 2029-09-08 Common Stock 235237 235237 D On August 22, 2020, the Issuer (formerly known as Proteostasis Therapeutics, Inc.) entered into an Agreement and Plan of Merger and Reorganization, as amended on November 6, 2020, with Pangolin Merger Sub, Inc. ("Merger Sub"), Yumanity, Inc. (formerly known as Yumanity Therapeutics, Inc.) and Yumanity Holdings, LLC ("Holdings"). On December 22, 2020, Merger Sub was merged with and into Yumanity, Inc., with Yumanity, Inc. surviving as a wholly-owned subsidiary of the Issuer (the "Merger"). Immediately prior to the consummation of the Merger, Holdings was merged with and into Yumanity, Inc., with Yumanity, Inc. as the surviving entity. 25% of the shares subject to the option vested on July 10, 2020. The remaining 75% vest in equal monthly installments over the subsequent three years. Received in the Merger in exchange for a stock option to acquire 1,115,708 shares of Yumanity, Inc. common stock for $1.72 per share. /s/ Marie Epstein, Attorney-in-Fact 2020-12-28